<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347751">
  <stage>Registered</stage>
  <submitdate>1/12/2011</submitdate>
  <approvaldate>5/12/2011</approvaldate>
  <actrnumber>ACTRN12611001241921</actrnumber>
  <trial_identification>
    <studytitle>A study to see if everolimus can enhance immune response to vaccination in the elderly.</studytitle>
    <scientifictitle>A multicenter, single-blind, placebo-controlled study to investigate effects of everolimus on the immune response to vaccination in the elderly.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Aging</healthcondition>
    <healthcondition>Immune response to vaccination.</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Elderly participants who meet eligibility during the 21 day screening period will be randomised to 1 of the treatment arms:
Arm 1 Evrolimus 0.5 mg by mouth daily  or unmatched placebo
Arm 2 Everolimus 5 mg by mouth weekly or matched placebo
Arm 3 Everolimus 20 mg by mouth weekly or unmatched placebo

During the screening period the Study Doctor will ask you about your health and your medical and (psychiatric) history. The doctor will do a physical exam and measure your height, weight, blood pressure, heart rate and breathing rate. You will be asked about any medications you have been taking. You will have a heart tracing (electrocardiogram [ECG]) and blood and urine will be taken for laboratory testing. You will have a chest X-ray done if you havent had one in the last 3 months.</interventions>
    <comparator>Unmatched placebo controlled study. Matching placebo is not available for all everolimus dosing forms. Both the everolimus and placebo tablets contain lactose anhydrous, polyvinylpolypyrolidone XL and magnesium stearate. In addition the placebo tablets contain celllulose HP-M-603 in place of everolimus.

The site will have a dedicated person assigned to give the study drugto the participant to ensure the study blind is maintained.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the safety and tolerability of low dose or intermittently dosed everolimus in the elderly. At baseline subjects will have blood drawn for saefty assessments and baseline titers to influenza, Hepatitus B and pneumoccoccus.  Patients will use diaries to record any adverse events. Blood will be drawn periodically throughout the study for saefty assessment.</outcome>
      <timepoint>At baseline and periodically throughout the study.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To assess the efficacy of low dose or intermittently dosed everolimus in enhancing the immune response to vaccination in the elderly.</outcome>
      <timepoint>As determined by the change in hemagglutination inhibition (HI) geometric mean titers 4 weeks post influenza vaccination.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the efficacy of low dose or intermittently dosed everolimus in enhancing the immune response to vaccination in the elderly .</outcome>
      <timepoint>As determined by rates of seroconversion and seroprotection 4 weeks post influenza vaccination.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male and female (postmenopausal or surgically sterile). 

Subjects must weight at least 40kg to participate.</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Subjects with underlying unstable medical conditions.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>12/12/2011</anticipatedstartdate>
    <actualstartdate>9/01/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>2/07/2012</actualenddate>
    <samplesize>210</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>27/04/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Institutes for BioMedical Research, Inc.</primarysponsorname>
    <primarysponsoraddress>220 Massachusetts Avenue
Cambridge, MA 02139</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Institutes for BioMedical Research, Inc.</fundingname>
      <fundingaddress>220 Massachusetts Avenue
Cambridge, MA 02139</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Novartis Pharmaceuticals Australia</sponsorname>
      <sponsoraddress>54 Waterloo Road
North Ryde, NSW 2113</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A multicenter study to see if everolimus has an effect on the immune response in elderly people.</summary>
    <trialwebsite />
    <publication>Not applicable.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Limited</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>2011-10-470</hrec>
      <ethicsubmitdate>5/10/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Multi-region Ethics Committee</ethicname>
      <ethicaddress>Level 1
1-3 The Terrace
Wellington 6011</ethicaddress>
      <ethicapprovaldate>21/11/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>3/10/2011</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Joan Mannick</name>
      <address>Novartis Institutes for BioMedical
Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139
USA</address>
      <phone>+1  617 8715659</phone>
      <fax />
      <email>joan.mannick@novartis.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Elaine Gent</name>
      <address>Level 2, Northern Steamship Building 
122-124 Quay St
Auckland CBD 1010</address>
      <phone>+64 3 384 1207</phone>
      <fax />
      <email>elaineg@pharmasols.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jeff Wall</name>
      <address>Suite G.07 MacArthur Point Building
25 Solent Circuit 
Baulkham Hills NSw 2153</address>
      <phone />
      <fax />
      <email>jeffw@pharmasols.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Gerard Foley</name>
      <address>Independent Practitioner Network Pty Ltd
The Mosman Practice
393 Military Road
Mosman, NSW
2088
</address>
      <phone> +61 2 9960 0634</phone>
      <fax />
      <email>gerard.foley@ipnet.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>